IP Library Granted Patent US 8,623,912
Granted Patent B2
US 8,623,912 · App. 12/896,144 · Granted Jan 7, 2014

Fostriecin derivatives and the pharmaceutical uses thereof

Inventors: Li Tang (Beijing, CN); Rongguo Qiu (Beijing, CN)
Assignees: Beijing Biostar Technologies, Ltd.; Dalian University of Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,623,912
App. No.
12/896,144
Granted
Jan 7, 2014
Kind
B2
Abstract

Novel Fostriecin (or FST) derivatives represented by formula (I), the pharmaceutical compositions and preparation methods thereof. The pharmaceutical uses of these compounds, especially the use for the preparation of pharmaceutical compositions for treating tumor, inhibiting cell over growth, or lowering myocardial infarction and the injury to cells.

Claims (22)

1. A compound of the following formula (I):

wherein,

R 1 is

R 1 is not a phosphate group;

R 2 , R 3 and R 4 are each independently selected from H, OH, OR 5 , NHR 6 and a lower alkyl group;

W is O, O—CRjRj or NRj;

G is P, S or C;

X is SR 6 , OR 5 or NHRj; as G is S, X═NRj or ═O;

Y is OR 5 , NHRj, CF 3 , an unsubstituted lower alkyl group or a lower alkyl group substituted by a hydroxyl group, a lower acyloxy group, a lower alkanoyl group, a lower alkoxyl group, an amino group, a halogen, a lower alkylamido group or a lower amido group;

R 5 and R 6 are each independently H, Na, K, or an unsubstituted lower alkyl group or a lower alkyl group substituted by a hydroxyl group, a lower acyloxy group, a lower alkanoyl group, a lower alkoxyl group, an amino group, a halogen, a lower alkylamido group or a lower amido group;

As G is C, X does not exist;

Rn is O, NRj or S;

Rj is H, OH, an alkyl group or a halogen.

2. The compound according to claim 1 , wherein R 1 is selected from the group consisting of:

and wherein R 7 is methyl or CF 3 .

3. The compound according to claim 1 having the following formula (III):

wherein Rj′ is H, OH, an alkyl group or a halogen.

4. The compound according to claim 1 , having one of the following formulas:

5. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical acceptable carrier and/or diluent.

6. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutical acceptable carrier and/or diluent.

7. A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutical acceptable carrier and/or diluent.

8. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutical acceptable carrier and/or diluent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2022
From: DALIAN UNIVERSITY OF TECHNOLOGY
To: BEIJING BIOSTAR PHARMACEUTICALS CO., LTD.
Reel/Frame 059971/0738 →
CHANGE OF NAME Recorded May 20, 2022
From: BEIJING BIOSTAR TECHNOLOGIES, LTD.
To: BEIJING BIOSTAR PHARMACEUTICALS CO., LTD.
Reel/Frame 060876/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2011
From: TANG, LI; QIU, RONGGUO
To: BEIJING BIOSTAR TECHNOLOGIES, LTD.; DALIAN UNIVERSITY OF TECHNOLOGY
Reel/Frame 025722/0092 →
Priority Claims (1)
CN 2008 1 0091830 · Apr 3, 2008 · national
Continuity (2)
Continuation PCTCN2009000366 · Apr 3, 2009
Related Publication 20120065171A1 · Mar 15, 2012